Quick Answer
Clearside Biomedical, Inc. reported Cash and Equivalents of $20.02 million for fiscal year 2024.
Clearside Biomedical, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $20.02M | -30.8% |
| 2023 | $28.92M | -40.1% |
| 2022 | $48.26M | +58.6% |
| 2021 | $30.44M | +76.1% |
| 2020 | $17.29M | -23.5% |
| 2019 | $22.59M | +180.9% |
| 2018 | $8.04M | -12.8% |
| 2017 | $9.22M | -73.5% |
| 2016 | $34.82M | +71.7% |
| 2015 | $20.28M | +145.3% |
| 2014 | $8.27M | +333.2% |
| 2013 | $1.91M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.80M | -51.0% | -27.5% |
| June 30, 2025 | $9.38M | -48.6% | -31.2% |
| March 31, 2025 | $13.63M | -61.5% | -31.9% |
| December 31, 2024 | $20.02M | -30.8% | +44.2% |
| September 30, 2024 | $13.89M | -51.8% | -23.9% |
| June 30, 2024 | $18.24M | -47.9% | -48.4% |
| March 31, 2024 | $35.35M | -14.6% | +22.3% |
| December 31, 2023 | $28.92M | -40.1% | +0.4% |
- Clearside Biomedical, Inc. showed a decrease of -30.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2024 period, Clearside Biomedical, Inc.’s cash and equivalents has grown by 948.7% (from $1.91 million to $20.02 million).
- The most recent figure is from Clearside Biomedical, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: